FDA Issues New Warning Letter to Compounders Over Semaglutide Salt Products

The FDA has issued a new warning letter targeting compounding pharmacies that continue to market semaglutide salt products. The agency says these products don’t contain the same active ingredient as FDA-approved GLP-1 drugs like Ozempic and Wegovy, raising questions about both their legality and their safety for patients. This latest action follows a series of enforcement steps the FDA has taken in recent months against compounders selling GLP-1-related products, and it signals that the agency isn’t backing down from its position that semaglutide salts are fundamentally different from the approved form of semaglutide.

The warning letter, published on March 16, 2026, calls out several compounding pharmacies by name for producing and distributing products labeled as semaglutide sodium or other semaglutide salt forms. According to the FDA, these salt forms are not interchangeable with the semaglutide base used in approved medications. Under federal law, compounders can only produce copies of commercially available drugs using the same active ingredient, and because semaglutide salts are chemically distinct from semaglutide base, the agency says these compounded versions fall outside the legal framework that permits compounding entirely.

The letter also raises sourcing concerns, with the FDA noting that some compounders may be obtaining their active pharmaceutical ingredients from suppliers who haven’t undergone proper FDA registration or inspection. This creates an additional layer of risk for patients who have no way to independently verify the quality or origin of the raw materials in their compounded prescriptions. Without the clinical data that supports the approved formulations, the FDA says there’s no guarantee that semaglutide salt products behave the same way in the body - differences in absorption, potency, and stability could all pose problems that patients and prescribers wouldn’t necessarily anticipate.

Compounders named in the letter have been given a specific window to respond and outline corrective actions, though the FDA hasn’t yet announced further enforcement measures. The tone of the letter, however, suggests the agency is prepared to escalate if compliance doesn’t follow. For patients currently using compounded semaglutide products, this is the practical concern: if your compounder is using a salt form of semaglutide, there’s a growing chance that product could be pulled from the market or face additional restrictions in the coming weeks.

This warning letter fits into a broader pattern of steadily increasing FDA pressure on the compounded GLP-1 market throughout early 2026. Previous actions targeted mass-marketed compounded products and unapproved formulations, while this latest letter narrows the focus specifically to the salt form question - a distinction that could affect a large number of compounders who’ve been operating under the assumption that their products were compliant. The question of whether semaglutide salts qualify as the “same active ingredient” has real financial stakes, and not everyone in the pharmaceutical or legal world agrees with the FDA’s interpretation, so industry observers expect at least some formal pushback from compounders or their trade associations.

It’s still unclear whether state pharmacy boards will take independent action based on the federal warning, adding yet another variable to watch. Patients and prescribers should monitor the FDA’s compounding page for updates, as additional warning letters or even injunctions could follow if the agency continues its recent pattern. The broader GLP-1 compounding market remains in flux, and until there’s either a definitive legal ruling or a clear regulatory framework addressing the salt form question, expect continued tension between the FDA and compounders who see surging patient demand they want to fill.